Javara, a leading integrated research organization (IRO) that delivers clinical trials at the point of care, announced it has secured significant Series C funding from earlier and new community-based investors. The funding will support expansion into new therapeutic specialties including Oncology, CNS, and Neurology through localized clinical research collaborations.
Strategic Growth Initiative
The Winston-Salem, North Carolina-based company, established in 2018, was founded with a vision to revolutionize the clinical trials industry by accelerating research access for patients, biopharma companies, and healthcare organizations. Founders Jennifer Byrne, Linda McCarty, and Amanda Wright positioned this funding as an essential step in advancing their mission.
"We are extremely grateful for the privilege and opportunity this funding secures as we move into an accelerated growth era for Javara," said Javara Founder and CEO Jennifer Byrne. "The support of a broadened group of community-based investors will amplify our impact greatly as we work to deliver community-based clinical trial access and education for more patients across the nation."
Current Market Position and Expansion Plans
Javara currently provides access to over 5 million patients across 7 states through strategic partnerships with healthcare organizations. The company now has the opportunity to double both patient and physician reach while developing new areas of therapeutic excellence that align with current primary public health concerns and the rapid evolution of the clinical trials industry.
The funding will specifically support the expansion of both current and new healthcare partnerships, allowing the company to grow into new therapeutic specialties through localized clinical research collaborations that increase patient access and amplify geographic footprint.
Clinical Research as a Care Option Model
As pioneers of Clinical Research as a Care Option (CRAACO), Javara partners with large healthcare organizations to deliver clinical trial access at the point of care through integrated research staff and infrastructure. The company's access to broad diverse patient populations through trusted physicians ensures clinical trials are completed with high enrollment and retention for quality data delivery.
Javara's centralized resources and standardized operations provide efficiencies for accelerated study start-up and quality outcomes, reducing obstacles in the product approval process. The organization's model transforms healthcare by connecting the right patients to the right trials at the right time.
Advisory Support
Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan advised Javara on the Series C funding round, while Crosstree Capital Partners acted as an advisor to the company during the funding process.
